Human Health

What Human Health does

Human Health is an integrated healthcare services provider headquartered in Kowloon City, Hong Kong, publicly listed on the Hong Kong Stock Exchange under ticker hkg:1419. Founded in 1997, the company operates with a workforce of 501-1,000 employees and maintains a multi-site clinical footprint consistent with an established healthcare delivery operator serving the Hong Kong market. Its core business is the provision of integrated healthcare services, with revenue mechanics implied to be patient-service-driven across clinical operations rather than software licensing or platform subscription.

In August 2025, the company initiated a strategic expansion beyond its core Hong Kong service-delivery model by developing RhinoMAP, an AI-powered respiratory disease detection and monitoring platform, and securing AUD $3 million in federal funding for the effort. The platform is being developed for the Australian healthcare market and is supported by a partnership with Diag-Nose.io, suggesting an AI-driven diagnostic and monitoring product line that layers on top of the existing clinical footprint. The platform represents a new product line moving the company from pure services delivery toward a hybrid services-plus-AI-platform model.

The input data contains material internal conflicts — including a separate set of blocks describing Human Health as a pre-revenue Australian AI startup, and financial figures in the trillion-dollar range that are clearly data corruption. Per source-precedence rules, the firmographic listing data (HKEX 1419, founded 1997, 501-1,000 employees, Hong Kong integrated healthcare services) is treated as the authoritative primary record, while the startup-style data blocks are noted as unresolved conflicting signals rather than merged into the baseline profile.

Name

Human Health

Website

https://humanhealth.com.hk

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Human Health is a Hong Kong-listed integrated healthcare services provider founded in 1997, operating multi-site clinical services from Kowloon City, now extending into AI-powered respiratory disease monitoring via the RhinoMAP platform.

Ownership category

akta.pro rank

Product category

Integrated Healthcare Services

NAICS

Home Health Care Services (621610)

SIC

Services-Health Services (8000)

akta.pro primary industry

Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension) (HLACAPAD)

akta.pro secondary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

Keywords

• Integrated healthcare services
• Respiratory disease monitoring
• AI healthcare platform
• Biomarker analysis
• Medical diagnostics

Headquarters

HQ city

Kowloon City

HQ country

Hong Kong SAR China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Healthcare Technology Solutions: Pre-revenue stage company developing AI-powered respiratory disease monitoring technology. Revenue model likely involves healthcare technology licensing, diagnostic services, and/or platform subscription fees once product is commercialized.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Human Health Holdings Limited is an integrated healthcare service provider headquartered in Kowloon City, Hong Kong, founded in 1997. The company delivers AI-powered healthcare platforms such as RhinoMAP, which uses biomarkers and artificial intelligence to perform real-time inflammation analysis for monitoring and treating respiratory diseases. Operations span healthcare service delivery alongside technology development through partnerships with research and medical institutions.

Product overview

Human Health operates primarily through its collaborative AI-powered platform RhinoMAP, developed in partnership with Diag-Nose.io. The platform represents the company's core offering focused on respiratory disease monitoring and treatment analysis using biomarkers and real-time inflammation data. The project, with a total cost of $8.4 million including $3 million in federal funding, involves partnerships with Australian research and medical entities.

Differentiator

Problem solved

Functional benefit

Products and services

• RhinoMAP AI-powered platform that uses biomarkers and artificial intelligence to provide real-time inflammation analysis for monitoring and treating respiratory diseases. Targeted at healthcare providers, hospitals, clinics, and medical research institutions requiring continuous treatment efficacy monitoring.
• Integrated Healthcare Services Integrated healthcare service delivery operations for patients and healthcare consumers, supported by 501-1000 employees across the Hong Kong-headquartered organization.

Quantifiable outcome

• Reduced healthcare costs for respiratory disease treatment through improved treatment efficacy
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Two partnerships are on record, tiered core and minor.

• Diag-Nose.iocoreStrategic or Co-development Partner · 25 August 2025Human Health and Diag-Nose.io are collaborating on the RhinoMAP project, a shared AI-powered respiratory disease monitoring platform. Both startups jointly secured $3 million in federal funding for this initiative, working together to develop treatment analysis capabilities using AI and biomarkers.
• Australian Research and Medical EntitiesminorStrategic or Co-development PartnerPartnerships with Australian research and medical entities involved in the RhinoMAP project, contributing clinical expertise, research capabilities, and access to patient data for respiratory disease monitoring platform development.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• TidalSense: TidalSense applies AI to respiratory diagnostics, including connected spirometry and lung-condition screening. Directly comparable to RhinoMAP in combining AI with physiological/biomarker signals for respiratory disease detection and monitoring.
• Adherium: Adherium develops connected inhaler sensors and a respiratory adherence platform for patients with asthma and COPD. Comparable to Human Health in using sensor/biomarker-driven data capture to improve respiratory treatment outcomes.
• Respiri (formerly Isonea): Respiri is an Australia-based respiratory health company developing wheeze/sound-based remote monitoring devices for asthma and COPD. Directly comparable in geography (Australian ecosystem), technology category (biomarker/AI respiratory monitoring), and target patient population.
• NuvoAir: NuvoAir is a digital health platform for chronic respiratory disease management combining connected spirometry, symptom tracking, and clinician dashboards. Highly comparable to Human Health's RhinoMAP in targeting AI-enabled remote monitoring of chronic respiratory patients through healthcare-provider channels.

Broad incumbents

• ResMed (Propeller Health): ResMed acquired Propeller Health, a digital respiratory health platform that uses sensors and AI to monitor inhaler use and respiratory conditions. Directly comparable to Human Health's RhinoMAP in applying connected monitoring and data analytics to chronic respiratory disease management.
• Philips Respiratory Care: Philips offers a broad portfolio of connected respiratory care solutions including COPD monitoring, ventilators, and remote patient management. Comparable as a large incumbent operating in the same respiratory monitoring and chronic-disease-management category.
• OMRON Healthcare (Respiratory): OMRON Healthcare manufactures connected respiratory monitors, nebulizers, and peak-flow devices for asthma and COPD management at global scale. Comparable as an incumbent respiratory-monitoring vendor whose device-plus-data strategy parallels Human Health's platform approach.

Emerging players

• Strados Labs: Strados Labs builds wearable respiratory monitoring devices that capture lung-sound biomarkers for clinical decision support. Closely aligned with Human Health's biomarker-plus-AI approach to continuous respiratory disease monitoring.
• Wellinks: Wellinks provides connected respiratory care management for COPD and other chronic lung diseases, combining wearables with digital coaching. Comparable to RhinoMAP in delivering AI/data-driven remote monitoring for chronic respiratory patients through healthcare partners.
• Aluna Medical: Aluna Medical has developed a spirometer-plus-app platform for asthma and COPD self-monitoring with clinician sharing. Directly comparable in the connected-spirometry/biomarker-monitoring category that overlaps with Human Health's RhinoMAP.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Human Health